Archives
Cisapride (R 51619): Transforming Cardiac Electrophysiolo...
Cisapride (R 51619): Transforming Cardiac Electrophysiology Research
Principle and Setup: Harnessing Cisapride for Mechanistic Discovery
Cisapride (R 51619) has emerged as a cornerstone compound in modern cardiac electrophysiology research, owing to its unique dual function as a nonselective 5-HT4 receptor agonist and a potent hERG potassium channel inhibitor. These properties make it indispensable for dissecting the interplay between serotonin-mediated signaling and ion channel function in arrhythmogenesis and drug-induced cardiotoxicity.
The compound’s high purity (99.70%), robust documentation (HPLC, NMR, MSDS), and solubility profile (≥23.3 mg/mL in DMSO; ≥3.47 mg/mL in ethanol) facilitate reproducible experimental design, especially in settings where precise pharmacological modulation is required. Researchers leverage Cisapride to interrogate:
- 5-HT4 receptor signaling pathways relevant to gastrointestinal motility and cardiac function
- hERG channel inhibition as a model for drug-induced long QT syndrome and arrhythmia risk
- Safety pharmacology screens in both primary and iPSC-derived models
Its insolubility in water and optimal storage at -20°C necessitate careful handling, but this is offset by its exceptional stability in solid form and compatibility with high-content screening platforms.
Step-by-Step Workflow: Integrating Cisapride into Cardiac and GI Models
1. Preparing Stock Solutions
- Dissolve Cisapride in DMSO to a concentration of 10–20 mM; vortex until fully dissolved.
- Aliquot and store at -20°C. Avoid repeated freeze-thaw cycles and long-term storage in solution.
2. Cell Culture and Experimental Design
- For cardiac arrhythmia research: Utilize human iPSC-derived cardiomyocytes (iPSC-CMs) seeded in high-content imaging plates (e.g., 96- or 384-well formats).
- For gastrointestinal motility studies: Employ primary enteric neuron cultures or GI smooth muscle cells, optimizing seeding density for functional assays.
3. Compound Titration and Treatment
- Perform an 8-point dose-response curve, typically ranging from 1 nM to 10 μM, to capture both 5-HT4 agonism and hERG inhibition windows.
- Add Cisapride or vehicle to cells, ensuring DMSO concentration remains ≤0.1% (v/v) in final media.
4. Phenotypic and Functional Readouts
- For cardiac electrophysiology: Use voltage-sensitive dyes, calcium imaging, or multi-electrode arrays (MEAs) to monitor action potential duration (APD), beat rate, and arrhythmic events.
- For GI motility: Assess cell contraction, migration, or neurotransmitter release using live-cell imaging platforms.
5. Data Analysis and Interpretation
- Integrate deep learning-based image analysis, as exemplified in the Grafton et al. (2021) eLife study, to classify cardiotoxic phenotypes with high sensitivity and specificity.
- Quantify dose-dependent effects, identifying thresholds for pro-arrhythmic or GI-modulatory activity.
Advanced Applications and Comparative Advantages
High-Content Cardiac Safety Pharmacology
Deep phenotypic screening using iPSC-CMs and Cisapride allows researchers to model clinical liabilities such as QT prolongation and torsades de pointes in vitro. In the referenced eLife study, high-content imaging combined with deep learning flagged compounds with hERG liability—Cisapride was a benchmark standard, consistently eliciting quantifiable arrhythmogenic signatures across multiple assays. For instance, APD prolongation exceeding 20% at ≥1 μM Cisapride is routinely observed, mirroring clinical risk thresholds.
Translational GI Motility Studies
As a nonselective 5-HT4 receptor agonist, Cisapride is instrumental in probing enteric neurotransmission and gut motility. Its actions contrast with more selective agonists, enabling broader pathway interrogation. This advantage is highlighted in this comparative review, which explores how Cisapride’s dual mechanism outperforms single-target agents when modeling complex GI pathophysiology.
Workflow Enhancement in Early Drug Discovery
Integrating Cisapride into safety pharmacology workflows streamlines hit-to-lead triage. Its robust, predictable hERG inhibition profile offers a stringent positive control for platform validation—critical for cross-project comparability and regulatory submissions. Insights from this article demonstrate how Cisapride enables precise dissection of 5-HT4 and hERG interplay, facilitating mechanistic deconvolution and off-target risk assessment in broad compound libraries.
Complementary and Contrasting Literature
- Complement: Unraveling Cardiac Electrophysiology extends the discussion by providing actionable strategies for de-risking cardiac liabilities using Cisapride in iPSC-CM models, echoing the translational impact seen in this workflow.
- Contrast: While Redefining Cardiac Electrophysiology Research contextualizes Cisapride within the competitive safety pharmacology landscape, this article focuses on hands-on protocol enhancements and troubleshooting for experimentalists.
- Extension: Cisapride in Translational Research extends these applications to innovative predictive screening and next-generation disease modeling, building on the workflows detailed here.
Troubleshooting and Optimization Tips
- Solubility Issues: Cisapride is insoluble in water; always dissolve in DMSO or ethanol. If precipitation occurs, warm gently (≤37°C) and vortex thoroughly. Filter sterilize if required for cell-based assays.
- Storage and Stability: Store solid Cisapride at -20°C. Prepare fresh working solutions immediately prior to use. Avoid storing diluted solutions for more than 24 hours to prevent degradation and loss of potency.
- DMSO Toxicity: Maintain final DMSO concentrations at or below 0.1% (v/v) in culture media to minimize confounding cytotoxicity.
- Assay Sensitivity: For MEA or optical mapping, baseline drift or electrical noise can mask subtle arrhythmic events. Use replicate wells and include vehicle controls to establish robust signal-to-noise windows.
- Batch Variability: Source Cisapride from suppliers providing comprehensive QC (HPLC, NMR, MSDS) to ensure experimental reproducibility—such as ApexBio.
For dose optimization, begin with literature-reported EC50/IC50 values: hERG inhibition IC50 ≈ 20–30 nM; 5-HT4 agonism EC50 ≈ 5–50 nM (model-dependent). Validate functional readouts with orthogonal methods (e.g., patch clamp, Ca2+ imaging) where possible.
Future Outlook: Cisapride as a Platform Molecule in Translational Research
The integration of Cisapride (R 51619) into high-throughput phenotypic platforms and advanced human-relevant models is redefining the boundaries of predictive toxicology and mechanistic pharmacology. With the advent of deep learning-based analytics—as pioneered in Grafton et al. (2021)—the sensitivity and scalability of arrhythmogenic risk assessment are poised for exponential growth.
Going forward, the synergistic use of Cisapride with gene-edited iPSC-CMs, patient-derived organoids, and multiplexed functional assays will further enable:
- Personalized safety profiling of investigational drugs
- Mechanistic deconvolution of complex arrhythmia syndromes
- Discovery of protective compounds that counteract hERG-mediated cardiotoxicity
Moreover, as machine learning continues to mature, the phenotypic fingerprints induced by Cisapride—across both cardiac and gastrointestinal domains—will catalyze new insights into off-target drug effects, rare adverse event prediction, and rational drug design.
For researchers seeking to de-risk drug candidates or elucidate the intricacies of 5-HT4 and hERG biology, Cisapride (R 51619) remains an indispensable and rigorously validated tool compound at the interface of discovery and translational science.